BNTX Jan 2025 155.000 call
| Previous close | 11.63 |
| Open | 11.63 |
| Bid | 8.10 |
| Ask | 8.90 |
| Strike | 155.00 |
| Expiry date | 2025-01-17 |
| Day's range | 11.63 - 11.63 |
| Contract range | N/A |
| Volume | |
| Open interest | 15 |
Motley FoolWhy Pfizer and BioNTech Stocks Zoomed Higher Today
The fight against COVID-19 isn't over yet, and the two companies remain very much in the battle.
Motley FoolWhy CureVac Stock Plunged Today
Shares of CureVac (NASDAQ: CVAC) were down 9.1% as of 2:45 p.m. ET Thursday after a German court temporarily suspended the biopharmaceutical company's patent trial against BioNTech (NASDAQ: BNTX). CureVac previously failed to develop a successful COVID-19 vaccine during the pandemic, opting instead to focus on potential second-generation vaccines in partnership with GlaxoSmithKline. BioNTech, by contrast, generated tens of billions of dollars in annual revenue from its successful mRNA vaccines developed in partnership with Pfizer.
Globe NewswirePfizer and BioNTech Receive Health Canada Authorization for XBB.1.5-Adapted Monovalent COVID-19 Vaccine
COMIRNATY Omicron XBB.1.5-adapted monovalent COVID-19 vaccine is now authorized in Canada for individuals 6 months of age and olderNew Omicron XBB.1.5-adapted COVID-19 vaccine is administered as a single dose for individuals 5 years of age and older, regardless of COVID-19 vaccination history. In children 6 months through 4 years of age the vaccine is administered as a three-dose series in those without a history of completion of a COVID-19 primary vaccination course, or as a single dose in thos
